UP
UPR.IR Uniphar Group PLC
- Market cap
- EUR 1.05B
- P/E
- 19.2x
- P/B
- 2.47x
- ROE
- 12.6%
- Dividend yield
- 0.48%
- Fundamental score
- 2.5/5
Ratios use the latest price and the fiscal year ending Dec 2025.
Is UPR.IR undervalued?
Graham numberUPR.IR trades 45.2% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Uniphar Group PLC fundamental analysis
12 of 22 checks passedROE 1/2
Moderate return on equity (12.0%), between 10% and 20%.
ROA 1/1
Return on assets (3.1%) is above the industry median (2.7%).
Profit Consistency 2/2
Profitable for 8 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Last year's EPS growth (-16.3%) is not above the 5-year average (13.2% a year).
Earnings Growth vs Industry 0/1
Last year's EPS growth (-16.3%) is below the industry median (1.4%).
Revenue Growth 2/2
Revenue grew 14.1% a year over the past 3 years.
Short-term Liquidity 0/1
Current assets do not cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 1/2
Moderate debt to equity (82.1%), up to 100%.
Debt Trend 1/1
Debt to equity has not risen over the past 5 years.
Debt Coverage 1/1
Operating cash flow covers 20% of total debt.
Interest Coverage 0/1
EBIT is 4.0x against interest expense, below 5x.
PE vs Market 0/1
PE (19.2x) is above the market median (15.7x).
PE vs Industry 1/1
PE (19.2x) is below the industry median (22.9x).
PBV 0/1
Price to book (2.5x) is above the industry median (1.4x).
Graham Number 0/1
The price is above the Graham number (PE x PB = 47.4, limit 22.5).
PEG 0/1
PEG on 5-year earnings growth is 1.46, above 1.
Dividend Yield 0/2
Dividend yield (0.5%) is in the bottom 25% of dividend payers in the market.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 1/1
Dividends paid grew over the past 5 years.
Payout Ratio 1/1
Payout ratio is 9.9%, covered by earnings.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Uniphar Group PLC stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Uniphar Group PLC
Uniphar plc, together with its subsidiaries, operates as a diversified healthcare services company in the Republic of Ireland, the United Kingdom, the Netherlands, and internationally. It operates through three divisions: Uniphar Medtech, Uniphar Pharma, and Uniphar Supply Chain & Retail. The company provides sales, marketing, servicing, quality, compliance, regulatory support, and distribution services to medical device manufacturers; high-value services across the life cyc…
Full company profileUniphar Group PLC financial statements
Uniphar Group PLC annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 1.30B | 1.27B | 1.55B | 1.67B | 1.82B | 1.94B | 2.07B | 2.55B | 2.77B | 3.07B |
| Gross Profit | 86.8M | 82.0M | 160M | 181M | 217M | 274M | 307M | 390M | 428M | 458M |
| Operating Income | 17.1M | 10.9M | 36.7M | 40.2M | 46.7M | 59.6M | 53.2M | 77.7M | 85.1M | 91.4M |
| EBITDA | 16.0M | 7.27M | 34.5M | 51.4M | 59.4M | 89.6M | 92.4M | 113M | 137M | 120M |
| Net Income | 5.74M | -1.03M | 17.3M | 21.0M | 27.8M | 48.1M | 45.6M | 44.8M | 64.2M | 51.1M |
| EPS | 0.02 | 0.00 | 0.06 | 0.11 | 0.11 | 0.18 | 0.17 | 0.16 | 0.24 | 0.20 |
| Balance Sheet | ||||||||||
| Total Assets | 288M | 290M | 655M | 761M | 840M | 945M | 1.11B | 1.29B | 1.42B | 1.73B |
| Total Liabilities | 298M | 300M | 506M | 580M | 638M | 693M | 821M | 956M | 1.01B | 1.33B |
| Shareholders' Equity | -10.2M | -10.5M | 149M | 181M | 202M | 251M | 290M | 333M | 402M | 405M |
| Cash & Short-term Investments | 15.0M | 1.19M | 107M | 114M | 60.4M | 78.0M | 104M | 85.7M | 103M | 184M |
| Total Debt | 64.4M | 54.6M | 166M | 183M | 218M | 245M | - | - | - | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | 23.7M | -1.68M | -8.74M | 107M | 66.0M | 52.2M | 82.8M | 52.5M | 124M | 108M |
| Capital Expenditure | 9.87M | 4.91M | 4.90M | 6.45M | 15.7M | 14.4M | 14.0M | 32.0M | 102M | 62.8M |
| Free Cash Flow | 13.8M | -6.59M | -13.6M | 101M | 50.2M | 37.7M | 62.9M | 20.6M | 22.2M | 45.6M |
| Ratios | ||||||||||
| ROE | - | - | 11.6% | 11.6% | 13.7% | 19.1% | 15.7% | 13.5% | 16.0% | 12.6% |
| ROA | 2.0% | -0.4% | 2.6% | 2.8% | 3.3% | 5.1% | 4.1% | 3.5% | 4.5% | 2.9% |
| Net Profit Margin | 0.4% | -0.1% | 1.1% | 1.3% | 1.5% | 2.5% | 2.2% | 1.8% | 2.3% | 1.7% |
| Debt to Equity | - | - | 1.11x | 1.01x | 1.08x | 0.98x | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Uniphar Group PLC dividends
- Dividend yield
- 0.48%
- Forward dividend
- 0.02 EUR
- Payout ratio
- 9.9%
- Ex-dividend date
- Sep 17, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | EUR 5.08M | 0.02 | 9.9% |
| 2024 | EUR 5.08M | 0.02 | 7.9% |
| 2023 | EUR 4.83M | 0.02 | 10.8% |
| 2022 | EUR 4.67M | 0.02 | 10.2% |
| 2021 | EUR 5.73M | 0.02 | 11.9% |
| 2020 | EUR 1.99M | 0.01 | 7.2% |
| 2019 | EUR 1.99M | 0.01 | 9.5% |
| 2018 | EUR 1.99M | 0.01 | 11.5% |
| 2017 | EUR 1.99M | 0.01 | - |
| 2016 | EUR 3.00K | 0.00 | 0.1% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Uniphar Group PLC
- Insiders 5.52%
- Institutions 51.37%
- Public & others 43.11%
- Shares outstanding 260M
- Free float 239M
Uniphar Group PLC company profile
- Company name
- Uniphar Group PLC
- Ticker
- UPR.IR
- ISIN
- IE00BJ5FQX74
- Exchange
- Irish Exchange
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Employees
- 3,500
- Fiscal year end
- December
- Address
- 4045 Kingswood Road, Dublin, Ireland, D24 V06K
- Phone
- 353 1 428 7777
- Website
- uniphar.ie
About Uniphar Group PLC
Uniphar plc, together with its subsidiaries, operates as a diversified healthcare services company in the Republic of Ireland, the United Kingdom, the Netherlands, and internationally. It operates through three divisions: Uniphar Medtech, Uniphar Pharma, and Uniphar Supply Chain & Retail. The company provides sales, marketing, servicing, quality, compliance, regulatory support, and distribution services to medical device manufacturers; high-value services across the life cycle of a pharmaceutical product; and healthcare professionals with access to medicines that cannot source through traditional channels. It is also involved in the pre-wholesale and wholesale distribution of pharmaceutical, healthcare, and animal health products to pharmacies, hospitals and veterinary surgeons; operates a network of pharmacies under the Life, Allcare, Hickey's, and McCauley brands. In addition, the company provides pharmacy support, pharmaceutical supply chain and services, medical device distribution, specialist nursing and infusion, outsourcing and resourcing, healthcare technology, medical affairs, online pharmacy and product fostering, pharmaceutical wholesale distributor, retail pharmacy software and technology, and telecommunications support services, as well as specialist provider of pharmaceuticals. Uniphar plc was founded in 1967 and is headquartered in Dublin, Ireland.
Uniphar Group PLC management
9- Mr. Gerard Rabbette B.Comm FCACEO & Executive Director
- Mr. Timothy Dolphin B.Comm FCACFO & Executive Director
- Mr. Allan Smylie C.F.A.Head of Strategy and Investor Relations
- Ms. Aisling McCarthyGeneral Counsel & Company Secretary
- Mr. Seamus EganHead of Corporate Development
- Mr. Brian O'ShaughnessyCCO and Commercial Lead of C&C Pharma & Product Access
- Mr. Dermot RyanManaging Director
- Ms. Kay BonavitaChief Commercial Officer for Uniphar Logistics
- Rick HughesManaging Director of Uniphar Logistics